Servier agreed to acquire Edgewise Therapeutics’ muscular dystrophy business for $1.55 billion upfront, with total deal value potentially reaching $2.65 billion including milestone payments. The transaction gives Servier control of the fast skeletal myosin inhibitor sevasemten (EDG-5506), which is in pivotal and Phase 2 development across rare neuromuscular disorders. Edgewise’s muscular dystrophy platform is expected to generate pivotal readouts by year-end, which could determine whether the asset becomes a cornerstone of Servier’s neurology and rare disease pipeline. The company framed the deal as part of a revenue growth strategy that extends beyond oncology. The acquisition also consolidates clinical development risk under a larger pharma balance sheet, potentially accelerating manufacturing and late-stage execution if trial outcomes remain on track. Edgewise and Servier each signaled the deal’s strategic intent, with the pricing structure tied to future development and regulatory achievements.